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Carcinoma ex pleomorphic adenoma is a rare tumor arising from the salivary glands that spreads through direct
extension, through the lymphatic vessels, and, rarely, hematogenously. When distant metastases have been found,
they have been reported mainly in the lung. We present an unusual case of carcinoma ex pleomorphic adenoma
of the parotid gland with splenic metastases. The patient presented with a primary carcinoma ex pleomorphic
adenoma of the parotid gland and he underwent a total parotidectomy with laterocervical lymphadenectomy
ipsilateral and adjuvant radiation therapy to the right parotid area. One year later, the patient showed an ipsilateral
supraclavicular lymph node recurrence, treated with surgery and radiation therapy. Two more years later, the
patient developed lung and splenic lesions, detected through CT and PET. He underwent splenectomy and
pathologic assessment of the specimen showed metastatic carcinoma ex pleomorphic adenoma. To our
knowledge, there is no reported case of a carcinoma ex pleomorphic adenoma metastasizing to the spleen.
Patients treated for carcinoma ex pleomorphic adenoma should be investigated for distant metastases with a
long-term follow-up examination for local and distant metastases and new splenic lesions in these patients should
be investigated.
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Pleomorphic adenoma (PA) is the most common tumor of
the salivary glands (it includes about 65% of all salivary
gland tumors). PA originates more commonly in parotid
glands (65% to 75%), 8% in submandibular glands, and
only 6% to 7% in minor salivary glands. Generally, it is
considered a benign and slow-growing tumor, but about
1.6% to 7.5% of PA shows malignant changes during its
natural history, including three different types: carcinoma
ex pleomorphic adenoma (CXPA), also called malignant
mixed tumor, carcinosarcoma, and metastasizing PA
(MPA); the latter two are exceedingly rare [1,2].* Correspondence: dr.rossi@ymail.com
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stated.Histologically, MPA cannot be differentiated from a
benign PA (it consists of the presence of both epithelial
and mesenchymal benign elements), but it is a malignant
aggressive entity; in fact, during its natural history it
manifests local or distant metastasis [3]. Carcinosarcoma
is composed of malignant epithelial and mesenchymal
components and it has a very aggressive course. CXPA
represents approximately 3% to 5% of all salivary gland
neoplasms and it predominantly arises from major saliv-
ary glands, more commonly from the parotid gland [4].
Misdiagnosis is common because the residual PA com-
ponent may be small, and because various carcinoma
subtypes may be present [5].
CXPA is a rare aggressive epithelial malignancy with
poor prognosis, frequently leading to local metastasis
and with a high mortality. Gnepp et al. found that 5-year
survival ranged from 25% to 65% and that the detection
of metastases is considered pre-terminal [6]. Importantd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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are stage, lymph node involvement, tumor type, histo-
logical grade, perineural invasion, and extent of invasion
[7]. However, because of its low incidence, no standard
treatment has been described so far. Surgery is the pri-
mary treatment for CXPA, and postoperative radiation
therapy plays an important role. Presently, no evidence
suggests that adjuvant chemotherapy can improve CXPA
prognosis [8]. CXPA spreads through a direct locoregio-
nal extension or lymphatic spread (typically to the cer-
vical lymph nodes), and rarely hematogenously. When
distant metastases are found, they have been reported
mainly in the lung, bone, and liver [9].
The clinical case reported below refers to the unusual
experience of our patient, affected by a CXPA metastatic
to the spleen. As far as we know, this is the first case to
be reported in the literature.
Case presentation
A 66-year-old man, presented to our hospital in February
of 2010, about five months after the occurrence of soft
tissue swelling on the right laterocervical area that had
gradually increased in size. An ultrasound and a CT scan
of the neck showed an inhomogeneous and irregular
lesion in the right laterocervical area. A biopsy of this
lesion was performed, indicating a carcinoma ex pleo-
morphic adenoma of the right parotid gland.
The patient underwent adjuvant radiation therapy
consisting of 1.50 Gy in 25 fractions and a boost of 2.10
Gy in 5 fractions to the right parotid area.
After a staging CT scan and a total parotidectomy with
ipsilateral laterocervical lymphadenectomy, a CXPA of
the right parotid infiltrating the skin surface and the
next muscle tissue of stage pT4a pN0 M0 was con-
firmed. Histologic examination showed a poorly differ-
entiated malignant epithelial component originated from
a pleomorphic adenoma. Immunohistochemically, cellsFigure 1 Histologic specimen of carcinoma ex pleomorphic adenoma
epithelial component in pleomorphic adenoma (A). Immunohistochemical
cytokeratins (B).were positive for p63 and a cocktail of cytokeratins.
Moreover, Ki67 labeling index was 50% (Figure 1).
The patient underwent adjuvant radiation therapy
consisting of 1.50 Gy in 25 fractions and a boost of 2.10
Gy in 5 fractions to the right parotid area.
In March of 2011, during a surveillance CT of the
neck an irregular and inhomogeneous lesion measuring
4 cm in the right supraclavicular region was detected.
The patient underwent dissection of right supraclavicu-
lar lymph nodes with histopathological confirmation of a
secondary localization of CXPA of salivary glands. The
patient was subjected to radiation therapy consisting of
50 Gy in 25 fractions to the right supraclavicular region.
Follow-up of the patient demonstrated no locoregional
recurrence or distant metastases; however, in February
of 2013 the patient underwent a surveillance CT scan
showing a low-density nodular lesion measuring 1.2 cm
in the apical segment of the upper lobe of the left lung
and another similar lesion measuring 2.5 cm in the
superior-medial portion of the spleen. Indeed, a PET
scan confirmed the presence of two hypercaptant le-
sions in the left lung (SUV 4.1) and in the spleen (SUV
10.6) (Figure 2).
The patient was referred to the Hematology Depart-
ment, who performed a bone marrow biopsy and ruled
out a hematological disease.
In April of 2013, the patient underwent a new CT scan
showing a low-density nodular lesion measuring 1.7 cm
in the apical segment of the upper lobe of the left lung
that had increased in volume and a hypovascular lesion
measuring 4.8 cm in the superior-medial portion of the
spleen, which had also increased in volume (Figure 3).
The patient was referred to the General Surgery Depart-
ment and underwent a laparoscopic splenectomy. This
operation became hard due to the presence of metastasis
displacing the hilar vessels. Histologic examination re-
vealed that three out of four of the removed lymphof the parotid. Image shows the poorly differentiated malignant
staining demonstrated strong and diffuse positivity for a cocktail of
Figure 2 18F-FDG PET images of splenic metastasis. Axial section (A) and coronal section (B).
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epitheliomorphic cells, arranged in solid nests and cords
with a round or oval nucleus and a large eosinophilic
cytoplasm. Few cellular monstrosities were present,
while necrosis was not observed. Immunohistochemi-
cally, these CXPA cells were specifically positive for
cytokeratin 7, S-100 protein, and p63, but were negative
for cytokeratin 20, smooth muscle actin, and gross cystic
disease fluid protein-15 (GCDFP-15). On the other hand,
Ki67 labeling index was 50%.
Morphology and immunohistochemical panels indi-
cated splenic and lymph node localization of a poorly
differentiated epithelial neoplasm, which was difficult to
classify histopathologically, probably originating from
the salivary glands (Figure 4).
Conclusion
PA of the salivary glands is generally considered a benign
neoplasm, but in 2% to 9% of cases it can undergo to
carcinomatous transformation (i.e., CXPA) [10]. CXPA is
a rare and poorly understood neoplasm developing from
either a long-standing primary or recurrent pleomorphic
adenoma. It typically occurs in patients in the 6th to 8th
decade of life. Increased preoperative duration of a PAFigure 3 CT images of splenic metastasis. Axial section (A) and coronalincreases the risk of malignant transformation into
CXPA [11]. Our patient was a 66-year-old man who
underwent surgery five months after the occurrence of
soft tissue swelling on the right laterocervical area.
CXPA contains both benign PA and carcinomatous
components in different proportions. In some cases, the
malignant component can completely replace the mixed
tumor, which usually leads to misdiagnosis. As reported
herein, it is worth noting that only the carcinomatous
component was present in the metastatic lesion.
The mechanism of malignant transformation of PA is
still unclear, although it probably depends on accumula-
tion of genetic instabilities [12]. CXPA is sub-classified
into non-invasive, minimally invasive (about 1.5-mm
penetration of the malignant component into the extra
capsular tissue), and invasive (more than 1.5-mm pene-
tration into the extra capsular tissue); treatment strat-
egies usually depend on this sub-classification [2].
Although any form of the above forms of carcinoma can
be observed as well as a mixture of subtypes, the WHO
states that the components of PA are most frequently a
poorly differentiated carcinoma (e.g., salivary duct carcin-
oma or adenocarcinoma, not otherwise specified) or an un-
differentiated carcinoma [2]. Advanced T stage and lymphsection (B).
Figure 4 Histologic specimen of splenic metastasis. The spleen is involved by atypical epitheliomorphic cells, arranged in solid nests and cords
with a round or oval nucleus and a large eosinophilic cytoplasm (A); immunohistochemical staining demonstrated positivity for cytokeratin 7 (B).
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nostic factors for an unfavorable clinical outcome [7]. The
extent of tumor infiltration beyond the capsule and, there-
fore, extraparotid invasion have been found to correlate
with CXPA recurrence and survival and they are some of
the most reliable prognostic factors [7].
Vascular and perineural invasion has a statistically sig-
nificant effect on distant metastases, tumor-specific sur-
vival, and overall survival, while high-grade tumors are
more likely to predict unfavorable clinical outcomes [4,7].
The presence of myoepithelial carcinoma subtype appears
to increase the risk of recurrence and p63 antigen may be
an useful marker of myoepithelial cells in salivary gland
neoplasms [13]. Aggressive tumors have a high MIB1
index (Ki67), which results in rapid growth [14].
Herein, the negative prognostic factors that indicated an
aggressive tumor biology as evidenced by its unusual
spread to the spleen were the advanced T stage (pT4a)
and the invasiveness. In fact, the primary tumor infiltrated
the skin surface and the next muscle tissue, while no vas-
cular or perineural invasion was described. Initially, latero-
cervical lymph nodes were not involved, but 1 year later
the tumor relapsed to the supraclavicular lymph nodes.
Furthermore, histologic examination of the primary and
secondary lesions revealed a poorly differentiated epithelial
neoplasm that was immunohistochemically positive for
p63. Moreover, Ki67 labeling index was high (50%).
Obviously, the prognosis also depends on the complete-
ness of the tumor resection and on the presence of locore-
gional recurrence or distant metastases. The prognosis after
detection of progression or recurrence is poor, with a me-
dian survival of less than 1 year. [7]CXPA can be asymp-
tomatic and often has similar clinical presentations as PA;
however, patients have a poor prognosis due to infiltrative
and destructive behavior and thus, early and accurate
diagnosis and aggressive surgical treatment can increase
their survival rates [4]. Total or radical parotidectomy isindicated for frankly invasive CXPA and neck dissection
should be performed for the majority of CXPA patients,
except for some intra-capsular or minimally invasive dis-
eases [4]. Postoperative radiation therapy is often used as
an adjuvant therapy in patients with adverse risk factors
and it significantly improves local control, but it does not
translate into a survival advantage [4,7].
In the evaluation of salivary gland tumors, the use of 18-
fluoro-2-deoxy-D-glucose positron emission tomography
(18F-FDG PET) remains a matter of debate. Kim et al. il-
lustrated an association between high FDG uptake and
Glut-1 overexpression in CXPA, and they noticed that it
could offer a basis for the clinical application of 18F-FDG
PET and Glut-1 for differential diagnosis between CXPA
and PA [15]. Otsuka et al. showed that FDG PET had a
significant impact on the management of patients with
salivary malignant tumors in both the initial staging and
restaging [16]. In our case, despite the proper therapeutic
management, the patient relapsed 1 year later. Moreover,
18F-FDG PET was useful for detection of metastases.
Generally, the spleen is a rare site of metastases. The
most common neoplasms spreading to the spleen re-
ported in the literature are breast, lung, colon and rec-
tum, ovary, and stomach. Splenic metastases arising
from head and neck cancers are exceedingly rare. Lam
et al. reviewed autopsies over a 25-year period and found
only 5 cases of splenic metastases originating from the
nasopharynx and 1 from the larynx [17]. There is 1 case
report of squamous cell carcinoma of the tonsil meta-
static to the spleen presenting as a splenic rupture [18],
while Raval et al. described a case of squamous cell car-
cinoma of the neck with splenic metastases treated with
laparoscopic splenectomy [19].
CXPA usually spreads through a direct locoregional ex-
tension and local lymphatic spread is the most common
means by which these tumors metastasize (typically to the
cervical lymph nodes). While reports of local recurrence
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geneous metastases have been reported. Distant metasta-
ses have been reported to occur in as many as 44% of
patients with CXPA [9]. Previously reported sites of hema-
togeneous metastases include the lungs (the most com-
mon site), pleura, pharynx, kidney, ocular choroid, liver,
bone, brain, and spinal cord [20-24].
In our case, both regional lymphatic and distant hema-
togeneous spread were identified. This case is exceptional
because, to our knowledge, it is the first case of salivary
gland tumor metastatic to the spleen and the first case of
CXPA metastatic to the spleen.
In conclusion, when recurrence or distant metastases
occur in CXPA, survival is very low. Although distant me-
tastases are rare, our case report remarks that patients
treated for CXPA should be investigated for distant metas-
tases with a long-term follow-up examination for local
and distant metastases. Moreover, our case underlines that
salivary gland tumors (even CXPA) can also metastasize to
the spleen and lesions seen in the spleen in a patient with
salivary gland tumors (even CXPA) should be further in-
vestigated with additional imaging.
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